DOCETAXEL AND IFOSFAMIDE AS SECOND LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CANCER AFTER FAILURE OF PLATINUM CHEMOTHERAPY: A PHASE 2 STUDY-Reference-Cited by-同舟云学术

DOCETAXEL AND IFOSFAMIDE AS SECOND LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CANCER AFTER FAILURE OF PLATINUM CHEMOTHERAPY: A PHASE 2 STUDY

Published:2001-01 Issue:1 Volume:165 Page:67-71
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

KREGE S.¹,REMBRINK V.¹,BÖRGERMANN C.H.¹,OTTO T.¹,RÜBBEN H.¹

Affiliation:

1. From the Department of Urology, University of Essen Medical School, Essen, Germany

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference17 articles.

1. Cancer of the bladder;Fair,1993

2. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors;Logothetis;J Clin Oncol,,1990

3. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Loehrer;J Clin Oncol,,1992

4. Combination of cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group Study;Meyers;J Urol,1992

5. Fluorouracil and recombinant interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors;Logothetis;J Natl Cancer Inst,,1991

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes;Annals of Oncology;2024-04

2. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors;Journal of Clinical Oncology;2021-08-01

3. Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience;Clinical Genitourinary Cancer;2020-06

4. Zweitlinientherapie des metastasierten Urothelkarzinoms;Der Urologe;2020-05-29

5. Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions;Journal of Oncology Practice;2019-08